Hansoh Pharmaceutical Group Company Limited ( simplified Chinese: 翰森制药集团有限公司; traditional Chinese: 翰森製藥集團有限公司; pinyin: Hànsēn Zhìyào Jítuán Yǒuxiàn Gōngsī) is a pharmaceutical company that manufactures and sells various types of medicine in mainland China. [1] It was founded in 1995 in Lianyungang, Jiangsu Province, China, by Zhong Huijuan, who is the company's chair. [2] Zhong and her family own 66% of the company. [3] It is the largest psychotropic drug producer in China. [4]
Hansoh Pharmaceutical had an initial public offering on the main board of the Hong Kong Stock Exchange ( SEHK: 3692) on 14 June 2019. [5] [6] [7] [8]
In August 2022, it was announced that the company's stock would be added to the Hang Seng Index. [9]
Hansoh Pharmaceutical Group Company Limited ( simplified Chinese: 翰森制药集团有限公司; traditional Chinese: 翰森製藥集團有限公司; pinyin: Hànsēn Zhìyào Jítuán Yǒuxiàn Gōngsī) is a pharmaceutical company that manufactures and sells various types of medicine in mainland China. [1] It was founded in 1995 in Lianyungang, Jiangsu Province, China, by Zhong Huijuan, who is the company's chair. [2] Zhong and her family own 66% of the company. [3] It is the largest psychotropic drug producer in China. [4]
Hansoh Pharmaceutical had an initial public offering on the main board of the Hong Kong Stock Exchange ( SEHK: 3692) on 14 June 2019. [5] [6] [7] [8]
In August 2022, it was announced that the company's stock would be added to the Hang Seng Index. [9]